BRCA Panel (BRCA1, BRCA2)
Also known as: Genetic Breast Cancer, Hereditary Breast Cancer, Hereditary Ovarian Cancer, BRACA
Use
Used to identify individuals with increased risk for hereditary breast and ovarian cancer syndrome, particularly in individuals with Ashkenazi Jewish ancestry and/or personal or family history of breast, ovarian, pancreatic, or metastatic or high‑grade prostate cancers. Genetic counseling and informed consent are strongly recommended before testing. Individuals with a positive result have a pathogenic or likely pathogenic variant in BRCA1 and/or BRCA2 and are at increased cancer risk; a negative result does not rule out risk. Panels do not detect all causes of hereditary predisposition, and variant classification may change over time. (Source: Quest Diagnostics FAQ)
Special Instructions
Not provided.
Limitations
Test is limited to BRCA1 and BRCA2 genes and does not assess other genes associated with hereditary breast cancer. Not all regions of these genes may be analyzed. Rare or novel variants may have unclear effects, and false positives or negatives may occur. Results should be interpreted in context of clinical findings, history, and other data; genetic counseling is recommended. (Sources: Quest FAQs)
Methodology
NGS (Targeted)
Biomarkers
BRCA1, BRCA2
Gene
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided
Container
lavender top tube (L)
Storage Instructions
ship ambient unless otherwise specified
Other tests from different labs that may be relevant